En español
NIDA

Menu

NIDA Notes Articles

NIDA Notes Category Graphic

Few Teens With Prescription Opioid Use Disorders Receive Treatment

July 2012

Fewer than 12 percent of adolescents who meet diagnostic criteria for prescription opioid abuse or dependence receive any treatment, according to an analysis of data from the 2005 to 2008 National Survey on Drug Use and Health. The most common reason the adolescents gave for not receiving treatment was their lack of perceived need for it.

NIDA Notes Category Graphic

Program Reduces Recidivism Among Men With Co-occurring Disorders

July 2012
A modified therapeutic community program designed by NIDA-supported researchers helped Colorado offenders with co-occurring substance use and mental health disorders re-enter their communities and avoid recidivism after release from prison.

NIDA Notes Category Graphic

PhenX Toolkit Provides Standard Measures for Research

July 2012
NIDA researchers working with human subjects now have a new resource at their fingertips: the PhenX Toolkit’s new Substance Abuse and Addiction (SAA) Collection. The Toolkit is designed to provide standardized measures, vetted and approved by the field, to help researchers compare and combine data from multiple studies.

NIDA Notes Category Graphic

Adolescent Smoking and Drinking at Historic Lows

July 2012
Rates of adolescent cigarette smoking and alcohol drinking stood at historic lows in 2011, but marijuana use trended upward, according to the Monitoring the Future (MTF) survey.

NIDA Notes Category Graphic

Prenatal Cocaine Exposure Increases Monkeys' Impulsivity Into Adulthood

July 2012

Prenatal drug exposure can have behavioral effects that last well into adulthood, according to two studies of adult monkeys prenatally exposed to cocaine. In the first study, drug-exposed monkeys exhibited less flexibility than controls in adjusting to changing circumstances; in the second study, drug-exposed males exhibited a greater preference than controls for having rewards right away, a sign of impulsivity.

NIDA Notes Category Graphic

Prevention System Has Lasting Effects, Benefit Exceeds Costs

July 2012

Towns that implemented a drug abuse prevention program called Communities That Care will see a return of $5.30 for each $1 they invested during the 5-year trial of the intervention, according to a cost-benefit analysis. The estimate is based on reductions in smoking and delinquency observed during the fourth year of the study among eighth-graders and the projected total costs of smoking, delinquency, and crime avoided over the lifetimes of study participants.

NIDA Notes Category Graphic

Training Gaps for Evidence-Based Practices

July 2012

Ninety percent of privately funded substance abuse treatment programs in the United States offer cognitive behavioral therapy (CBT)...

NIDA Notes Category Graphic

More Convenient Preparations of Buprenorphine Pass Test

July 2012
Soluble-film preparations of buprenorphine suppressed heroin abusers’ withdrawal symptoms with no serious side effects in a recent clinical trial. They dissolved more rapidly in the mouth than the pill form of the medication, providing faster relief.

NIDA Notes Category Graphic

The Present and Promise of mHealth

July 2012
NIDA researchers have developed a computer program that motivates and encourages treatment-seeking when an individual is in a primary care physician’s waiting room. Users of the program, called Video Doctor, enter information on a portable device and receive feedback about health risks related to their drug abuse, along with advice, immediately prior to seeing their physician.

NIDA Notes Category Graphic

Buprenorphine During Pregnancy Reduces Neonate Distress

July 2012

Sublingual buprenorphine is a safe and effective alternative to methadone for treating opioid dependence during pregnancy, finds the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study, a NIDA-supported clinical trial. Women who received either medication had similar pregnancy and birth outcomes, but infants born to women who received buprenorphine had milder symptoms of neonatal opioid withdrawal.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics